Trial Profile
MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors or Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Carboplatin; Docetaxel; Erlotinib; Everolimus; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Leukaemia; Solid tumours
- Focus Adverse reactions
- Acronyms MEK114375
- Sponsors GlaxoSmithKline; Novartis
- 24 Dec 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 17 Feb 2019 Status changed to discontinued.
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.